ELV
Elevance Health Inc.
ELV trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over ELV overall, supported by stronger fundamentals and stronger modeled upside.
ELV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Stable |
ELV's cash flow is currently healthy, and its revenue, profitability and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ELV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $333 | -22% |
| Forward | 15x | $430 | — |
| Fair | 18x | $416 | -3.3% |
| Current | 18x | $430 | — |
| Expensive | 20x | $470 | +9.4% |
Historical ranges are pointers, not guarantees.
ELV has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ELV Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Moderate | |
| Low |
Analysts expect ELV's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ELV on the outlook, with more favorable revenue and profitability expectations.
ELV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $28.82 | +22% |
| Q3 2026 | $23.54 | -4% |
| Q2 2026 | $22.59 | -4.2% |
| Q1 2026 | $23.60 | -8.2% |
| Q4 2025 | $25.21 | -1.8% |
| Q3 2025 | $24.53 | -11% |
| Q2 2025 | $23.57 | -18% |
| Q1 2025 | $25.70 | -3.1% |
| Q4 2024 | $25.68 | +1.8% |
ELV earned $23.54 per share over the past year, down 4% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ELV on earnings, with more consistent year-over-year improvement.
ELV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $51.4B | +1.4% |
| Q2 2026 | $50.5B | +1.4% |
| Q1 2026 | $50.2B | +2.6% |
| Q4 2025 | $49.7B | +9.5% |
| Q3 2025 | $50.7B | +12% |
| Q2 2025 | $49.8B | +13% |
| Q1 2025 | $48.9B | +15% |
| Q4 2024 | $45.4B | +6.6% |
ELV's revenue has grown year over year every quarter since late 2020: $51.4B last quarter, up 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.5% | -0.1 points |
| Q2 2026 | 3.5% | -1.4 points |
| Q1 2026 | 4.2% | -2.3 points |
| Q4 2025 | 0.6% | -0.9 points |
| Q3 2025 | 2.5% | -0.6 points |
| Q2 2025 | 4.9% | -1.4 points |
| Q1 2025 | 6.5% | -0.6 points |
| Q4 2024 | 1.5% | -1.5 points |
ELV's operating margin was 2.5% last quarter, about level with the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ELV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ELV on profitability, with a higher operating margin.
ELV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1B | +29% |
| Q2 2026 | $1.6B | -9% |
| Q1 2026 | $4.1B | +399% |
| Q4 2025 | -$209M | -154% |
| Q3 2025 | $775M | -67% |
| Q2 2025 | $1.8B | +1341% |
| Q1 2025 | $821M | -52% |
| Q4 2024 | $384M | +$3.7B |
ELV still generates free cash flow, though less than at its 2023 peak: $6.5B over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ELV on cash flow, with more consistent year-over-year improvement.
ELV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -300K shares |
| 1 year | -2.7% | -6.1M shares |
| 3 years | -8% | -18.9M shares |
| 5 years | -12% | -28.4M shares |
| Available history | -16% | -42.7M shares |
ELV has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $330M |
| Q2 2026 | $234M |
| Q1 2026 | $1.1B |
| Q4 2025 | $471M |
| Q3 2025 | $876M |
| Q2 2025 | $378M |
| Q1 2025 | $880M |
| Q4 2024 | $1.8B |
ELV spent $2.2B buying back its own shares over the past year, down 45% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ELV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Moderate |
| Q2 2026 | 3.0x | Moderate |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.6x | Moderate |
ELV's net debt is about 3.0 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ELV on leverage, with a lower net debt burden relative to earnings.
ELV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.8 | Neutral |
| Stochastic | 68.7 | Neutral |
ELV's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ELV PE vs Healthcare Sector
| Metric | ELV | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 57 | 29 | 28 pts above |
ELV has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ELV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $417.4 | 3% above |
| 20 week MA | $406.3 | 5.8% above |
| 50 week MA | $373.0 | 15% above |
| 100 week MA | $368.4 | 17% above |
| 200 week MA | $424.7 | 1.2% above |
ELV has climbed back above all five of its weekly moving averages, and it's now 1.2% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ELV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $306.4 | $308.7 | +0.7% |
| 2021 | $308.7 | $455.7 | +48% |
| 2022 | $455.7 | $514.3 | +13% |
| 2023 | $514.3 | $471.6 | -8.3% |
| 2024 | $471.6 | $371.1 | -21% |
| 2025 | $371.1 | $349.9 | -5.7% |
| 2026 YTD | $349.9 | $429.9 | +23% |
ELV has finished three years in a row lower, and it's up 23% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ELV on returns for 2026, with the stronger performance.